Use of sildenafil or other phosphodiesterase inhibitors and risk of melanoma

Background: Phosphodiesterase 5A inhibitors (PDEIs), a common treatment for erectile dysfunction, were recently linked to an increased risk of melanoma. Methods: We conducted two parallel case–control studies, using the Danish Nationwide Health Registries (DNHR) and the Kaiser Permanente Northern Ca...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer 2016-09, Vol.115 (7), p.895-900
Hauptverfasser:	Pottegård, Anton, Schmidt, Sigrún Alba Johannesdottir, Olesen, Anne Braae, Achacoso, Ninah, Van Den Eeden, Stephen K, Hallas, Jesper, Sørensen, Henrik Toft, Friis, Søren, Habel, Laurel A
Format:	Artikel
Sprache:	eng
Schlagworte:	692/4028/67/1813/1634 692/4028/67/2324 692/700/565/1436 692/700/565/2194 Aged Biomedical and Life Sciences Biomedicine California - epidemiology Cancer Research Case-Control Studies Causality Confidence intervals Cyclic Nucleotide Phosphodiesterases, Type 5 - physiology Denmark - epidemiology Dose-Response Relationship, Drug Drug dosages Drug Resistance Electronic health records Epidemiology Erectile dysfunction Health care Humans Linked Data Male Medical research Melanoma Melanoma - enzymology Melanoma - epidemiology Melanoma - pathology Middle Aged Molecular Medicine Neoplasm Invasiveness Neoplasm Proteins - physiology Neoplasm Staging Odds Ratio Oncology Patient Acceptance of Health Care Pharmacy Phosphodiesterase 5 Inhibitors - adverse effects Phosphodiesterase 5 Inhibitors - therapeutic use Proto-Oncogene Proteins B-raf - physiology Public health Ratios Sildenafil Citrate - adverse effects Sildenafil Citrate - therapeutic use Skin cancer
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!